X4 Pharmaceuticals Other Stockholder Equity Over Time
| XFOR Stock | USD 0.39 0.04 11.43% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out X4 Pharmaceuticals Performance and X4 Pharmaceuticals Correlation. XFOR |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of X4 Pharmaceuticals. If investors know XFOR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about X4 Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.08) | Revenue Per Share 0.003 | Return On Assets (0.40) | Return On Equity 0.2177 |
The market value of X4 Pharmaceuticals is measured differently than its book value, which is the value of XFOR that is recorded on the company's balance sheet. Investors also form their own opinion of X4 Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is X4 Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because X4 Pharmaceuticals' market value can be influenced by many factors that don't directly affect X4 Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, X4 Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Stockholder Equity Analysis
Compare X4 Pharmaceuticals and related stocks such as Terns Pharmaceuticals, Day One Biopharmaceu, and PDS Biotechnology Corp Other Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TERN | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 455 K | 1.2 M | 14.6 M | 342.7 M | 520.2 M | 588 M | 617.4 M |
| DAWN | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | 92.6 M | 408.6 M | 601.8 M | 805.1 M | 418.6 M |
| PDSB | 693.5 K | 693.5 K | 693.5 K | 693.5 K | 2 M | 184.8 M | 190.5 M | 214.6 M | 223.1 M | 40.6 M | 70.9 M | 123.9 M | 145.6 M | 170.6 M | 136.7 M |
| INZY | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | (76.5 M) | 79.8 M | 256.9 M | 333.4 M | 426.4 M | 447.7 M |
| ABOS | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | 65 M | 353 M | 359.9 M | 489.5 M | 276.8 M |
| MREO | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 113.7 M | 100 M | 118.2 M | 118.2 M | 138.7 M | 294.7 M | 383.2 M | 488.1 M | 484.9 M | 273.7 M |
| ELEV | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (7.2 M) | (97.1 M) | 46.4 M | 199.5 M | 250.8 M | 263.3 M |
| HEPA | (900) | (900) | (900) | 2.5 M | 2.5 M | 17.4 M | 32.2 M | 67.5 M | 76.7 M | 97.7 M | 142.9 M | 224.8 M | 223.9 M | 230.3 M | 241.8 M |
| HOOK | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 108.1 M | 81.8 M | 309.3 M | 317.1 M | 397.3 M | 467 M | 264.5 M |
X4 Pharmaceuticals and related stocks such as Terns Pharmaceuticals, Day One Biopharmaceu, and PDS Biotechnology Corp Other Stockholder Equity description
My Equities
My Current Equities and Potential Positions
| X4 Pharmaceuticals | XFOR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.39
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.